KZIA
Kazia Therapeutics LimitedHealthcare·Biotechnology
$12.78
$21M market cap
Revenue
$0.0M
Free Cash Flow
$-9.1M
Rev Growth
+0.0%
FCF Margin
-46038.4%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeuti
2-Year Price History
$13.66+9.5%
Quarterly Financials & Projections
Quarterly Waterfall (AUD M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q2 | 0.0 | -13.3 | -13.3 | -12.3 | -9.1 | -9.1 | -0.0 | 69.4 | 0.1 | 3.1 | -48.5% | -- | -- |
| Act | 2025-Q4 | 0.0 | -4.9 | -4.9 | -10.0 | -4.1 | 0.0 | -4.1 | 4.3 | 0.4 | 1.6 | <-999% | -- | -- |
Valuation & Metrics
Market Stats
Price$12.78
Market Cap$21M
Enterprise Value$-40M
P/S Ratio1461.6x
P/FCF--
EV/FCF--
FCF Margin (TTM)-46038.4%
FCF Yield-31.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-22.3M
Free Cash Flow$-9.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin-92090.1%
Net Margin-113004.6%
FCF Margin-46038.4%
CapEx % of Revenue21017.0%
SBC % of Revenue0.0%
ROIC-842.0%
WC Change % Rev1273.6%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.4M
Days to Cover1.2
Change (vs Prior)+119.5%
Need at least 2 settlement dates for chart
Employees
Headcount9
Revenue / Employee$2,190
Gross Profit / Employee$2,190
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
60.2%(+56.1% YoY)
23 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.0%(+0.0% YoY)
0 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
0 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Bleichroeder LP | $3.0M | $6.89 | +$0 | +$3.0M | -2.8% | $579M |
| Stonepine Capital Management, LLC | $2.6M | $6.89 | −$857K | +$2.6M | -5.9% | $113M |
| Point72 Asset Management, L.P. | $1.5M | $6.89 | +$0 | +$1.5M | +0.9% | $54.88B |
| BALYASNY ASSET MANAGEMENT LLC | $1.4M | $7.44 | +$1.4M | +$1.4M | -0.4% | $48.01B |
| PUTNAM FL INVESTMENT MANAGEMENT CO | $1.1M | $7.44 | +$1.1M | +$1.1M | -0.2% | $6.71B |
| Velan Capital Investment Management LP | $1.0M | $6.89 | −$1.2M | +$1.0M | -5.3% | $160M |
| Dauntless Investment Group, LLC | $594K | $6.75 | +$594K | +$594K | +4.8% | $35.6M |
| Sequoia Financial Advisors, LLC | $446K | $7.44 | +$446K | +$446K | -0.1% | $17.56B |
| Westside Investment Management, Inc. | $375K | $7.10 | +$145K | +$375K | +0.8% | $649M |
| ROYAL BANK OF CANADA | $255K | $6.89 | −$147K | +$255K | -0.2% | $526.36B |
| BARCLAYS PLC | $179K | $6.27 | +$0 | +$179K | -0.1% | $279.69B |
| RAYMOND JAMES FINANCIAL INC | $117K | $7.44 | +$117K | +$117K | -0.0% | $322.69B |
| UBS Group AG | $104K | $7.23 | +$102K | +$104K | -0.3% | $562.11B |
| Rockefeller Capital Management L.P. | $94K | $7.25 | +$15K | +$94K | -0.1% | $56.28B |
| Laird Norton Wetherby Trust Company, LLC | $92K | $7.44 | +$92K | +$92K | -0.6% | $4.58B |
| Qube Research & Technologies Ltd | $79K | $7.44 | +$79K | +$79K | +0.3% | $70.36B |
| FNY Investment Advisers, LLC | $74K | $7.03 | +$19K | +$74K | -0.7% | $225M |
| ADVISOR GROUP HOLDINGS, INC. | $65K | $7.44 | +$65K | +$65K | -0.3% | $67.63B |
| GAMMA Investing LLC | $12K | $7.25 | +$10K | +$12K | -0.5% | $2.14B |
| RHUMBLINE ADVISERS | $10K | $6.66 | −$1K | +$10K | +0.4% | $116.90B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.95%
avg per quarter
Holders (ex-self)
-1.96%
excl. this stock
Buyers (this Q)
+0.50%
14 buyers · $0.00B in
Sellers (this Q)
-5.18%
4 sellers · $0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-7.1%
how holders react when this stock falls
On quiet Qs
-48.0%
−10% to +10% baseline
On rallies (+10%+)
+1.9%
how they react when this stock rises
Holders' portfolio flow this Q
+2.3%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.8%
Sellers' overall flow ~ flat.
Biggest decreases this quarter
Alyeska Investment Group, L.P.exited−$5.1MVelan Capital Investment Management LP−$1.2Mα-5.3Empery Asset Management, LPexited−$1.2MStonepine Capital Management, LLC−$857Kα-5.9CORSAIR CAPITAL MANAGEMENT, L.P.exited−$470KROYAL BANK OF CANADA−$147Kα-0.2Engineers Gate Manager LPexited−$72KArax Advisory Partnersexited−$1KRHUMBLINE ADVISERS−$1Kα+0.4CITIGROUP INCexited−$0
New buyers this quarter
BALYASNY ASSET MANAGEMENT LLC+$0.00Bα-0.4PUTNAM FL INVESTMENT MANAGEMENT CO+$0.00Bα-0.2Sequoia Financial Advisors, LLC+$0.00Bα-0.1RAYMOND JAMES FINANCIAL INC+$0.00Bα-0.0Laird Norton Wetherby Trust Company, LLC+$0.00Bα-0.6Qube Research & Technologies Ltd+$0.00Bα+0.3BNP PARIBAS FINANCIAL MARKETS+$0.00Bα-0.2
Top-5 holders · 73.0%
Bleichroeder LP--
Stonepine Capital Management, LLC--
Point72 Asset Management, L.P.--
BALYASNY ASSET MANAGEMENT LLC--
PUTNAM FL INVESTMENT MANAGEMENT CO--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Alyeska Investment Group, L.P.—Stonepine Capital Management, LLC345KBleichroeder LP400KVelan Capital Investment Management LP135KPoint72 Asset Management, L.P.200KBALYASNY ASSET MANAGEMENT LLC193KEmpery Asset Management, LP—PUTNAM FL INVESTMENT MANAGEMENT CO142KDauntless Investment Group, LLC80KCORSAIR CAPITAL MANAGEMENT, L.P.—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$25.009560.0%
Last Year (3 analysts)$21.006430.0%
Current Price$12.78
Analyst Ratings
2
Buy: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
26.3%retail-2.9pp
13.2%dark-0.2pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Kazia Therapeutics Limited: Dilution-Fueled Survival Amidst Accounting Restatements and Chronic Insolvency
Overall Risk
9/10
Fraud
5/10
Dilution
10/10
Insolvency
9/10
Earnings Overstated
7/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
9/10
Hidden Upside
4/10
Contextually Acceptable
3/10